Recent advances in transarterial therapy of primary and secondary liver malignancies

Radiographics

Volumn 28, Issue 1, 2008, Pages 101-117

  Kalva, Sanjeeva P ^a   Thabet, Ashraf ^a   Wicky, Stephan ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; RADIOISOTOPE;

CONFERENCE PAPER; GENE THERAPY; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; LIVER TUMOR; METASTASIS;

ANTINEOPLASTIC AGENTS; GENE THERAPY; HUMANS; INJECTIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; RADIOISOTOPES;

EID: 38349178596     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.281075115     Document Type: Conference Paper

References (60)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55(1):10-30.
2. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001;33(1):62-65.
3. Llovet JM. Treatment of hepatocellular carcinoma. Curr Treat Options Gastroenterol 2004;7(6):431-441.
4. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 1985;56(4):918-928.
5. Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 2002;53(4):810-821.
6. Sasson AR, Sigurdson ER. Surgical treatment of liver metastases. Semin Oncol 2002;29(2):107-118.
7. Curley SA, Izzo F, Delrio P, et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg 1999;230(1):1-8.
8. Morris DL, Ross WB, Iqbal J, McCall JL, King J, Clingan PR. Cryoablation of hepatic malignancy: an evaluation of tumor marker data and survival in 110 patients. Gastrointest Cancer 1996;1:247-251.
9. Poon MA, O'Connell MJ, Moertel C, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7(10):1407-1418.
10. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. Meta-Analysis Group in Cancer. J Natl Cancer Inst 1996;88(5):252-282.
11. Breedis C, Young C. The blood supply of neoplasms in the liver. J Pathol 1954;30(5):969-977.
12. Salem R, Thurston KG. Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. II. Special topics. J Vasc Interv Radiol 2006;17(9):1425-1439.
13. 99mTc-MAA) uptake by colorectal liver metastases to response following Selective Internal Radiation Therapy (SIRT). BMC Nucl Med 2005;5:7.
14. Sarfaraz M, Kennedy AS, Cao ZJ, et al. Physical aspects of yttrium-90 microsphere therapy for nonresectable hepatic tumors. Med Phys 2003;30(2):199-203.
15. Ramsey DE, Kernagis LY, Soulen MC, Geschwind JF. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 2002;13(9 pt 2):S211-S221.
16. Konno T. Targeting cancer chemotherapeutic agents by use of lipiodol contrast medium. Cancer 1990;66(9):1897-1903.
17. Nakamura H, Hashimoto T, Oi H, Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989;170(3 pt 1):783-786.
18. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002;359(9319):1734-1739.
19. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35(5):1164-1171.
20. Hong K, Georgiades CS, Geschwind JF. Technology insight: image-guided therapies for hepatocellular carcinoma - intra-arterial and ablative techniques. Nat Clin Pract Oncol 2006;3(6):315-324.
21. Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007;46(3):474-481.
22. Murthy R, Nunez R, Szklaruk F, et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. RadioGraphics 2005;25:S41-S55.
23. Salem R, Thurston KG. Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. III. Comprehensive literature review and future direction. J Vasc Interv Radiol 2006;17(10):1571-1594.
24. Kulik LM, Mulcahy MF, Hunter RD, Nemcek AA, Abecassis MM, Salem R. Use of yttrium-90 microspheres (TheraSphere) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation: a case report. Liver Transpl 2005;11(9):1127-1131.
25. Gray B, Van Hazel G, Hope M, et al. Randomised trial of SIR-spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001;12(12):1711-1720.
26. 90Yttrium microspheres for extensive colorectal liver metastases. J Gastrointest Surg 2001;5(3):294-302.
27. Lewis AL, Gonzalez MV, Lloyd AW, et al. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 2006;17(2 pt 1):335-342.
28. Johnson PJ, Kalayci C, Dobbs N, et al. Pharmacokinetics and toxicity of intaarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol. J Hepatol 1991;13(1):120-127.
29. Hong K, Khwaja A, Liapo E, Torbenson MS, Georgiades CS, Geschwind JF. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 2006;12(8):2563-2567.
30. Lefrak EA, Pitha J, Rosenheim S, Gottlieb SA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32(2):302-314.
31. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35(3):421-430.
32. Kim W, Clark TWI, Baum RA, Soulen MC. Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol 2001;12(8):965-968.
33. Song SY, Chung JW, Han JK, et al. Liver abscess after transcatheter oily chemoembolization for hepatic tumors: incidence, predisposing factors, and clinical outcomes. J Vasc Interv Radiol 2001;12(3):313-320.
34. Geschwind JF, Kaushik S, Ramsey DE, Choti MA, Fishman EK, Koeiter H. Influence of a new prophylactic antibiotic therapy on the incidence of liver abscesses after chemoembolization treatment of liver tumors. J Vasc Interv Radiol 2002;13(11):1163-1166.
35. Geschwind JF, Salem R, Carr BI, Soulen MC, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004;127(5 suppl 1):S194-S205.
36. Lewin K, Millis RR. Human radiation hepatitis: a morphologic study with emphasis on the late changes. Arch Pathol 1973;96(1):21-26.
37. Miller FH, Keppke AC, Reddy D, et al. Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. AJR Am J Roentgenol 2007;188(3):776-785.
38. Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. I. Technical and methodologic considerations. J Vasc Interv Radiol 2006;17(8):1251-1278.
39. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5(6):649-655.
40. Liu DM, Salem R, Bui JT, et al. Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol 2005;16(7):911-935.
41. Ho S, Lau WY, Leung TW, et al. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med 1997;24(3):293-298.
42. Salem R, Lewandowski R, Roberts C, et al. Use of yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol 2004;15(4):335-345.
43. Houle S, Yip T, Shepherd F, et al. Hepatocellular carcinoma: pilot trial of treatment with Y-90 microspheres. Radiology 1989;172(3):857-860.
44. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205-216.
45. Keppke AL, Salem R, Reddy D, et al. Imaging of hepatocellular carcinoma after treatment with Yttrium-90 microspheres. AJR Am J Roentgenol 2007;188(3):768-775.
46. Deng J, Miller FH, Rhee TK, et al. Diffusion-weighted MR imaging for determination of hepatocellular carcinoma response to Yttrium-90 radioembolization. J Vasc Interv Radiol 2006;17(9):1195-1200.
47. 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2007;18(1 pt 1):49-56.
48. Mantravadi RV, Spigos DG, Tan WS, Felix EL. Intra-arterial yttrium 90 in the treatment of hepatic malignancy. Radiology 1982;142(3):783-786.
49. Herba MJ, Illescas FF, Thirlwell MP, et al. Hepatic malignancies: improved treatment with intraarterial Y-90. Radiology 1988;169(2):311-314.
50. Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005;16(12):1627-1639.
51. Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 2000;41(10):1673-1681.
52. Murthy R, Xiong H, Nunez R, et al. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol 2005;16(7):937-945.
53. Van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 2004;88(2):78-85.
54. Avila MA, Berasain C, Sangro B, and Prieto J. New therapies for hepatocellular carcinoma. Oncogene 2006;25(27):3866-3884.
55. Mesnil M, Yamasaki H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res 2000;60(15):3989-3999.
56. Fillat C, Carrio M, Cascante A, Sangro B. Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. Curr Gene Ther 2003;3(1):13-26.
57. Herraiz M, Beraza N, Solano A, et al. Liver failure caused by herpes simplex virus thymidine kinase plus ganciclovir therapy is associated with mitochondrial dysfunction and mitochondrial DNA depletion. Hum Gene Ther 2003;14(5):463-472.
58. Penuelas I, Mazzolini G, Boan JF, et al. Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology 2005;128(7):1787-1795.
59. Wang L, Schmitz V, Perez-Mediavilla A, Izal I, Prieto J, Qian C. Suppression of angiogenesis and tumor growth by adenoviral-mediated gene transfer of pigment epithelium-derived factor. Mol Ther 2003;8(1):72-79.
60. Sun XY, Wu ZD, Hu JB. Suicide gene therapy of hepatocellular carcinoma and delivery procedure and route of therapeutic gene in vivo. Hepatobiliary Pancreat Dis Int 2002;1(3):373-377.